MELD-Na Score

The MELD-Na Score Calculator incorporates serum sodium into the traditional MELD score, improving mortality prediction in patients with chronic liver disease. Hyponatremia is common in advanced cirrhosis, occurring in up to 30% of hospitalized patients, and independently predicts waitlist mortality beyond what the original MELD score captures. The MELD-Na was adopted by the United Network for Organ Sharing (UNOS) in January 2016 as the official scoring system for liver transplant allocation in the United States, replacing the original MELD score.

The pathophysiology of hyponatremia in cirrhosis relates to portal hypertension and systemic vasodilation. Splanchnic arterial vasodilation (mediated by nitric oxide) leads to effective arterial underfilling, triggering non-osmotic release of antidiuretic hormone (ADH), activation of the renin-angiotensin-aldosterone system, and sympathetic nervous system activation. The resulting water retention dilutes serum sodium, producing dilutional hyponatremia. The severity of hyponatremia closely reflects the degree of circulatory dysfunction and portal hypertension.

The MELD-Na formula modifies the original MELD score as follows: MELD-Na = MELD + 1.32 x (137 - Sodium) - 0.033 x MELD x (137 - Sodium). Sodium values are bounded between 125 and 137 mEq/L for this calculation. When sodium is 137 or above, the MELD-Na equals the original MELD score. As sodium decreases below 137, the MELD-Na score increases, reflecting the additional mortality risk. The interaction term (0.033 x MELD x Na difference) ensures that sodium has a greater impact at lower MELD scores, where it provides the most additional prognostic information.

The clinical significance of the sodium correction is substantial. Studies have shown that among patients with similar MELD scores, those with hyponatremia have significantly higher waitlist mortality. For example, a patient with MELD 15 and sodium 125 has mortality comparable to a patient with MELD 20 and normal sodium. By incorporating sodium, the MELD-Na score reclassifies approximately 7-10% of patients into higher priority categories, improving transplant allocation equity for those with complications not fully captured by the original three-variable MELD.

Hyponatremia in cirrhosis also has direct clinical consequences beyond its prognostic significance. Severe hyponatremia (sodium below 120 mEq/L) can cause confusion, seizures, and cerebral edema. Even moderate hyponatremia (125-130 mEq/L) impairs quality of life, increases fall risk, and worsens hepatic encephalopathy. Management involves fluid restriction, discontinuation of diuretics, and in refractory cases, administration of vasopressin receptor antagonists (vaptans) such as tolvaptan, though their use in cirrhosis requires careful monitoring due to concerns about overly rapid sodium correction and liver toxicity.

The MELD-Na represents an important iteration in the evolution of liver disease prognostic scoring. While it improves upon the original MELD, further refinements continue. The recently introduced MELD 3.0 score incorporates sodium along with albumin and sex into a completely redesigned formula, addressing additional disparities and prognostic gaps. Understanding both the MELD-Na and evolving scoring systems is essential for clinicians involved in the care of patients with advanced liver disease.